Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicitySvetlana O. Doronina, Peter D. Senter, Alan F. Wahl et al.|Bioconjugate Chemistry|2005Cited by 511
Contribution of Linker Stability to the Activities of Anticancer ImmunoconjugatesStephen C. Alley, Peter D. Senter, Dennis R. Benjamin et al.|Bioconjugate Chemistry|2008Cited by 464
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug ConjugateNicole M. Okeley, Stephen C. Alley, Jamie B. Miyamoto et al.|Clinical Cancer Research|2010Cited by 386
<i>In vivo</i>Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin ImmunoconjugateRussell J. Sanderson, Alan F. Wahl, Michelle A. Hering et al.|Clinical Cancer Research|2005Cited by 280
A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation TechnologyScott C. Jeffrey, Peter D. Senter, Patrick Burke et al.|Bioconjugate Chemistry|2013Cited by 246